Trader consensus implies an 80.5% probability that the CDC will not issue any Level 4 "Avoid All Travel" Travel Health Notice for a disease by December 31, 2026, reflecting the absence of active Level 4 alerts and no escalations from recent Level 2 notices for meningococcal disease in the Democratic Republic of the Congo (issued March 24), yellow fever in Venezuela (March 16), and chikungunya in Mayotte (March 10). These outbreaks show contained transmission dynamics per CDC surveillance, falling short of Level 4 criteria—extreme life-threatening risks with negligible mitigation options, as seen in past Ebola or peak COVID scenarios. Global polio remains at Level 1 despite multi-country spread, underscoring epidemiological stability. Upcoming CDC updates and WHO reports could shift odds if novel high-fatality strains emerge, but current data indicate low baseline risk for escalation.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · UpdatedCDC issues Level 4 warning by December 31?
CDC issues Level 4 warning by December 31?
$71,241 Vol.
$71,241 Vol.
$71,241 Vol.
$71,241 Vol.
A Level 4 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.
Market Opened: Jan 19, 2026, 3:15 PM ET
Resolver
0x65070BE91...A Level 4 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.
Resolver
0x65070BE91...Trader consensus implies an 80.5% probability that the CDC will not issue any Level 4 "Avoid All Travel" Travel Health Notice for a disease by December 31, 2026, reflecting the absence of active Level 4 alerts and no escalations from recent Level 2 notices for meningococcal disease in the Democratic Republic of the Congo (issued March 24), yellow fever in Venezuela (March 16), and chikungunya in Mayotte (March 10). These outbreaks show contained transmission dynamics per CDC surveillance, falling short of Level 4 criteria—extreme life-threatening risks with negligible mitigation options, as seen in past Ebola or peak COVID scenarios. Global polio remains at Level 1 despite multi-country spread, underscoring epidemiological stability. Upcoming CDC updates and WHO reports could shift odds if novel high-fatality strains emerge, but current data indicate low baseline risk for escalation.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated



Beware of external links.
Beware of external links.
Frequently Asked Questions